Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lightlake Therapeutics is set to initiate a Phase II trial evaluating nasal spray for the treatment of overweight and obese patients suffering from Binge Eating Disorder.
Subscribe to our email newsletter
The company expects to conclude the Phase II trials in early next year.
Lightlake intends to conduct Phase III trial at Imperial College London and other international institutions.
Further, the company will work with Celesio to develop a pharmacist delivered treatment program, and intends to establish similar commercial relationships over the next 12 months.
Lightlake CEO Roger Crystal said they recently completed stability testing in an effort to ensure that their nasal spray adheres to internationally recognised safety standards in delivering an effective treatment.
"Moreover, we have control group in place, as we were able to select 138 patients from over 900 applicants wanting to participate in our trials in Helsinki," Crystal said.